Johnson & Johnson (JNJ) Minority Interest (2010 - 2023)
Johnson & Johnson's (JNJ) quarterly Minority Interest came in at $1.3 billion in Q3 2023, up 113.56% quarter-over-quarter from $590.0 million in Q1 2010.
Analysis
Johnson & Johnson (JNJ) Minority Interest (2010 - 2023) Analysis & Trends
Johnson & Johnson has disclosed Minority Interest across 2 years of filings, most recently posting $1.3 billion for Q3 2023.
- In Q3 2023, Minority Interest changed N/A year-over-year to $1.3 billion; the TTM figure through Jul 2023 stood at $1.3 billion (changed N/A YoY), while the FY2010 annual figure was $590.0 million, changed N/A from the prior year.
- Minority Interest came in at $1.3 billion for Q3 2023 at Johnson & Johnson, up from $590.0 million in the prior quarter.
- In the past five years, Minority Interest ranged from a high of $1.3 billion in Q3 2023 to a low of $1.3 billion in Q3 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.14 Bn | 620.38 Bn | 17.26 Bn |
| 2 | AbbVie | 451.04 Bn | 444.47 Bn | 12.70 Bn |
| 3 | Merck | 357.43 Bn | 350.29 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 157.52 Bn | 145.82 Bn | 10.94 Bn |
| 6 | Sanofi | 52.14 Bn | 44.76 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 42.88 Bn | 42.88 Bn | - |
| 8 | Incyte | 24.70 Bn | 20.16 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.47 Bn | 18.80 Bn | 683.80 Mn |
| 10 | Neurocrine Biosciences | 15.82 Bn | 15.43 Bn | 935.80 Mn |